AMLX RSI Chart
Last 7 days
8.3%
Last 30 days
-25.2%
Last 90 days
-87.0%
Trailing 12 Months
-93.4%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 111.9M | 201.5M | 291.1M | 380.8M |
2022 | 0 | 0 | 11.3M | 22.2M |
2021 | 0 | 0 | 0 | 285.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 16, 2024 | cohen joshua b | acquired | - | - | 179,850 | co-chief executive officer |
Apr 16, 2024 | klee justin b. | acquired | - | - | 179,850 | co-chief executive officer |
Apr 16, 2024 | bedrosian camille l | acquired | - | - | 96,910 | chief medical officer |
Apr 16, 2024 | frates james m | acquired | - | - | 91,180 | chief financial officer |
Apr 16, 2024 | mazzariello gina | acquired | - | - | 80,560 | chief legal officer |
Mar 05, 2024 | klee justin b. | sold | -77,439 | 18.7279 | -4,135 | co-chief executive officer |
Mar 05, 2024 | mazzariello gina | sold | -28,841 | 18.7279 | -1,540 | chief legal officer |
Mar 05, 2024 | frates james m | sold | -33,560 | 18.7279 | -1,792 | chief financial officer |
Mar 05, 2024 | cohen joshua b | sold | -77,439 | 18.7279 | -4,135 | co-chief executive officer |
Feb 26, 2024 | mazzariello gina | acquired | - | - | 36,667 | chief legal officer |
Which funds bought or sold AMLX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 06, 2024 | Marquette Asset Management, LLC | unchanged | - | 198 | 1,094 | -% |
May 06, 2024 | HighTower Advisors, LLC | reduced | -4.14 | 406,000 | 21,146,000 | 0.03% |
May 06, 2024 | VitalStone Financial, LLC | added | 377 | 847,000 | 1,022,000 | 0.78% |
May 06, 2024 | Advisory Services Network, LLC | sold off | -100 | -13,453 | - | -% |
May 06, 2024 | Aveo Capital Partners, LLC | new | - | 3,432,550 | 3,432,550 | 0.37% |
May 06, 2024 | Parallel Advisors, LLC | new | - | 10,692 | 10,692 | -% |
May 06, 2024 | BBJS FINANCIAL ADVISORS, LLC | new | - | 914 | 914 | -% |
May 06, 2024 | ORG Partners LLC | sold off | -100 | -89,379 | - | -% |
May 06, 2024 | HighTower Advisors, LLC | reduced | -20.74 | -150,000 | 744,000 | -% |
May 06, 2024 | GREAT VALLEY ADVISOR GROUP, INC. | new | - | 213,872 | 213,872 | 0.01% |
Unveiling Amylyx Pharmaceuticals, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Amylyx Pharmaceuticals, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 46.4B | 6.8B | -7.77 | 6.77 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.5B | 2.0B | -58.76 | 9.74 | ||||
BMRN | 15.7B | 2.5B | 76.35 | 6.35 | ||||
INCY | 12.2B | 3.8B | 16.38 | 3.24 | ||||
MID-CAP | ||||||||
APLS | 5.3B | 524.1M | -12.77 | 10.17 | ||||
BBIO | 5.2B | 107.9M | -9.51 | 48.09 | ||||
AXSM | 3.7B | 251.0M | -12.33 | 14.56 | ||||
ARWR | 3.1B | 240.7M | -10.44 | 12.18 | ||||
ACAD | 2.8B | 726.4M | -46.38 | 3.91 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 24.99 | 4.48 | ||||
NVAX | 645.2M | 983.7M | -1.18 | 0.66 | ||||
CRBP | 424.2M | 881.7K | -12.56 | 481.06 | ||||
INO | 259.6M | 4.9M | -1.92 | 53.35 | ||||
IBIO | 7.1M | 2.1M | -0.26 | 2.14 |
Amylyx Pharmaceuticals, Inc. News
Income Statement (Quarterly) | |||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2021Q4 | 2021Q3 |
Revenue | 5.6% | 108,449,000 | 102,693,000 | 98,216,000 | 71,428,000 | 53,642,250 | 35,856,500 | 18,070,750 | 285,000 |
Costs and Expenses | 26.8% | 106,515,000 | 83,973,000 | 78,015,000 | 73,481,000 | 66,478,000 | 55,026,000 | - | 23,203,000 |
S&GA Expenses | 7.2% | 52,241,000 | 48,718,000 | 43,391,000 | 44,006,000 | 40,844,000 | 29,940,000 | 14,921,000 | 10,350,000 |
R&D Expenses | 49.5% | 44,914,000 | 30,037,000 | 29,044,000 | 24,192,000 | 22,813,000 | 24,914,000 | 13,394,000 | 12,853,000 |
EBITDA Margin | 535.4% | 0.15 | 0.02 | -0.35 | -1.32 | -8.87 | -10.96 | -308 | - |
Income Taxes | 17.0% | 1,776,500 | 1,518,000 | 1,900,000 | -200,000 | 553,500 | -100,000 | - | - |
Earnings Before Taxes | -71.1% | 6,476,000 | 22,411,000 | 24,007,000 | 1,403,000 | -42,125,000 | -53,881,000 | -28,344,000 | -23,142,000 |
EBT Margin | 628.8% | 0.14 | 0.02 | -0.35 | -1.33 | -8.89 | -10.98 | -308 | - |
Net Income | -77.4% | 4,731,000 | 20,893,000 | 22,074,000 | 1,573,000 | -42,704,000 | -53,756,000 | -28,344,000 | -23,142,000 |
Net Income Margin | 1951.9% | 0.13 | 0.01 | -0.36 | -1.33 | -8.92 | -10.99 | -308 | - |
Free Cashflow | 338.8% | 13,195,000 | -5,526,000 | 8,331,000 | -5,322,000 | -50,317,000 | -43,537,000 | -28,430,000 | -21,018,000 |
Balance Sheet | ||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | 10.9% | 517 | 467 | 454 | 408 | 391 | 181 | 225 | 274 | 106 |
Current Assets | 7.0% | 465 | 434 | 427 | 389 | 382 | 172 | 216 | 265 | 105 |
Cash Equivalents | 25.8% | 170 | 135 | 248 | 115 | 63.00 | 108 | 67.00 | 110 | 50.00 |
Inventory | 18.4% | 38.00 | 32.00 | 25.00 | 13.00 | 10.00 | 1.00 | - | - | - |
Net PPE | -2.7% | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 2.00 | 1.00 | 0.00 |
Liabilities | 74.4% | 84.00 | 48.00 | 67.00 | 55.00 | 51.00 | 37.00 | 32.00 | 33.00 | 17.00 |
Current Liabilities | 79.8% | 82.00 | 46.00 | 64.00 | 52.00 | 47.00 | 33.00 | 27.00 | 28.00 | 17.00 |
Shareholder's Equity | 3.6% | 433 | 418 | 386 | 353 | 341 | 144 | 193 | 241 | -151 |
Retained Earnings | 1.5% | -304 | -309 | -330 | -352 | -354 | -311 | -257 | -203 | -155 |
Additional Paid-In Capital | 1.4% | 738 | 728 | 717 | 705 | 695 | 456 | 451 | 445 | 5.00 |
Shares Outstanding | 0.3% | 68.00 | 68.00 | 67.00 | 67.00 | 67.00 | 59.00 | 58.00 | 52.00 | 7.00 |
Float | - | - | - | 1,310 | - | - | - | 788 | - | - |
Cashflow (Quarterly) | |||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 |
Cashflow From Operations | 362.2% | 13,551 | -5,169 | 8,609 | -5,072 | -49,697 | -43,078 | -46,462 | -40,634 | -28,244 | -20,865 | -13,047 | -12,643 |
Share Based Compensation | -6.3% | 9,534 | 10,176 | 9,950 | 7,501 | 6,091 | 5,524 | 5,707 | 4,392 | 1,091 | 802 | 657 | 586 |
Cashflow From Investing | 119.4% | 20,925 | -108,088 | 123,222 | 55,994 | -228,180 | 84,041 | 4,462 | -99,311 | 2,814 | -49,206 | - | -14.00 |
Cashflow From Financing | -74.1% | 230 | 889 | 1,384 | 1,040 | 232,162 | - | -828 | 200,455 | -1,065 | 131,651 | 1,993 | 25,927 |
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Revenues: | |||
Product revenue, net | $ 380,786 | $ 22,230 | |
Revenue from Contract with Customer, Product and Service [Extensible Enumeration] | us-gaap:ProductMember | us-gaap:ProductMember | |
Grant revenue | $ 285 | ||
Total revenues | $ 380,786 | $ 22,230 | 285 |
Operating expenses: | |||
Cost of sales | 25,441 | 2,993 | |
Research and development | 128,187 | 93,450 | 44,040 |
Selling, general and administrative | 188,356 | 127,128 | 38,933 |
Total operating expenses | 341,984 | 223,571 | 82,973 |
Income (loss) from operations | 38,802 | (201,341) | (82,688) |
Other income (expense), net: | |||
Interest income | 16,155 | 4,291 | 36 |
Change in fair value of convertible notes | (5,228) | ||
Other expense, net | (660) | (551) | (51) |
Total other income (expense), net | 15,495 | 3,740 | (5,243) |
Income (loss) before income taxes | 54,297 | (197,601) | (87,931) |
Provision for income taxes | 5,026 | 774 | |
Net income (loss) | $ 49,271 | $ (198,375) | $ (87,931) |
Net income (loss) per share-basic | $ 0.73 | $ (3.39) | $ (13.35) |
Net income (loss) per share-diluted | $ 0.7 | $ (3.39) | $ (13.35) |
Weighted-average shares used in computing net income (loss) per share-basic | 67,234,465 | 58,495,587 | 6,586,349 |
Weighted-average shares used in computing net income (loss) per share-diluted | 69,991,340 | 58,495,587 | 6,586,349 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 170,201 | $ 62,526 |
Short-term investments | 201,161 | 284,419 |
Accounts receivable, net | 40,050 | 15,306 |
Inventories | 38,323 | 9,769 |
Prepaid expenses and other current assets | 14,931 | 10,113 |
Total current assets | 464,666 | 382,133 |
Property and equipment, net | 2,686 | 2,611 |
Restricted cash equivalents | 719 | 719 |
Operating lease right-of-use assets | 3,725 | 5,524 |
Long-term inventories | 44,957 | |
Other assets | 701 | 466 |
Total assets | 517,454 | 391,453 |
Current liabilities: | ||
Accounts payable | 22,061 | 6,257 |
Accrued expenses | 57,724 | 38,312 |
Operating lease liabilities, current portion | 2,257 | 2,040 |
Total current liabilities | 82,042 | 46,609 |
Operating lease liabilities, net of current portion | 1,980 | 4,237 |
Total liabilities | 84,022 | 50,846 |
Commitments and contingencies (Note 18) | ||
Stockholders' equity: | ||
Preferred stock, $0.0001 par value; 10,000,000 shares authorized | ||
Common stock, $0.0001 par value; 300,000,000 shares authorized; 67,707,432 and 66,512,011 shares issued and outstanding as of December 31, 2023 and 2022, respectively | 7 | 7 |
Additional paid-in capital | 738,177 | 694,906 |
Accumulated deficit | (304,949) | (354,220) |
Accumulated other comprehensive income (loss) | 197 | (86) |
Total stockholders"equity | 433,432 | 340,607 |
Total liabilities, redeemable convertible preferred stock and stockholders' equity | $ 517,454 | $ 391,453 |